Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
MyChesCo on MSN1mon
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic ShockWARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated patient enrollment for its SEISMiC C trial, ...
Zacks Small Cap Research on MSN2mon
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected MilestonesThe New York Heart Association (NYHA) classification of heart failure ... expects to report results from its small Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback